Myovant Sciences Ltd. (NYSE:MYOV) Expected to Announce Earnings of -$0.44 Per Share

Equities research analysts expect Myovant Sciences Ltd. (NYSE:MYOV) to report earnings of ($0.44) per share for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Myovant Sciences’ earnings, with estimates ranging from ($0.58) to ($0.32). Myovant Sciences posted earnings per share of ($0.75) during the same quarter last year, which would suggest a positive year-over-year growth rate of 41.3%. The business is expected to announce its next quarterly earnings results on Thursday, November 11th.

According to Zacks, analysts expect that Myovant Sciences will report full-year earnings of ($2.24) per share for the current financial year, with EPS estimates ranging from ($2.69) to ($1.85). For the next year, analysts expect that the business will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.90) to ($0.41). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Myovant Sciences.

Myovant Sciences (NYSE:MYOV) last announced its quarterly earnings results on Wednesday, July 28th. The company reported ($0.67) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.46). The firm had revenue of $41.06 million during the quarter, compared to analyst estimates of $61.19 million.

Several equities analysts recently issued reports on MYOV shares. Zacks Investment Research lowered Myovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, August 10th. SVB Leerink began coverage on Myovant Sciences in a report on Thursday, September 9th. They set a “market perform” rating and a $24.00 price target on the stock. JMP Securities restated a “buy” rating on shares of Myovant Sciences in a report on Wednesday, August 25th. Finally, The Goldman Sachs Group began coverage on Myovant Sciences in a report on Friday, August 20th. They set a “neutral” rating and a $18.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Myovant Sciences presently has a consensus rating of “Hold” and an average price target of $25.57.

In other news, major shareholder Chemical Co. Ltd. Sumitomo purchased 48,167 shares of the company’s stock in a transaction that occurred on Monday, August 16th. The shares were purchased at an average price of $21.37 per share, for a total transaction of $1,029,328.79. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ferreira Juan Camilo Arjona sold 1,978 shares of the firm’s stock in a transaction that occurred on Friday, August 27th. The stock was sold at an average price of $22.69, for a total value of $44,880.82. The disclosure for this sale can be found here. In the last quarter, insiders bought 730,601 shares of company stock worth $16,713,133 and sold 32,709 shares worth $759,981. Corporate insiders own 5.10% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in MYOV. Commonwealth Equity Services LLC grew its stake in Myovant Sciences by 8.8% during the 1st quarter. Commonwealth Equity Services LLC now owns 11,578 shares of the company’s stock worth $238,000 after buying an additional 938 shares during the last quarter. Swiss National Bank lifted its position in Myovant Sciences by 1.6% during the 1st quarter. Swiss National Bank now owns 82,800 shares of the company’s stock worth $1,704,000 after acquiring an additional 1,300 shares during the period. BNP Paribas Arbitrage SA lifted its position in Myovant Sciences by 4,336.5% during the 1st quarter. BNP Paribas Arbitrage SA now owns 3,771 shares of the company’s stock worth $78,000 after acquiring an additional 3,686 shares during the period. Cambridge Investment Research Advisors Inc. lifted its position in Myovant Sciences by 12.1% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 38,655 shares of the company’s stock worth $796,000 after acquiring an additional 4,165 shares during the period. Finally, BlackRock Inc. lifted its position in Myovant Sciences by 432.0% during the 1st quarter. BlackRock Inc. now owns 955,352 shares of the company’s stock worth $19,662,000 after acquiring an additional 775,758 shares during the period. Hedge funds and other institutional investors own 33.78% of the company’s stock.

MYOV opened at $23.57 on Monday. The stock’s 50-day moving average price is $22.20 and its 200 day moving average price is $21.68. Myovant Sciences has a 12-month low of $13.42 and a 12-month high of $30.90. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of -7.53 and a beta of 2.87.

About Myovant Sciences

Myovant Sciences, Inc is a clinical-stage biopharmaceutical company. The firm focuses on the development and commercialization of therapies for the treatment of women’s health and endocrine diseases. It offers ORGOVYXTM (relugolix), a oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer.

Recommended Story: Treasury Bonds

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.